Viscosupplementation Market Forecast to 2027; Analyzed by Product (Single, Three, Five Injection) and End-use (Hospitals, Orthopedic Clinics/ASCs)

DUBLIN, March 12, 2020 /PRNewswire/ -- The "Viscosupplementation Market Size, Share & Trends Analysis Report by Product (Single Injection, Three Injection, Five Injection), by End-use (Hospitals, Orthopedic Clinics/ASCs), and Segment Forecasts, 2020 - 2027" report has been added to ResearchAndMarkets.com's offering.

http://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

The global viscosupplementation market size is expected to reach USD 7.8 billion by 2027. It is anticipated to exhibit a CAGR of 9.2% during the forecast period.

Improving regulatory and reimbursement scenarios regarding the use of viscosupplements for the treatment of Osteoarthritis (OA) is expected to aid the growth. For instance, in the U.S., unique reimbursement codes are allocated for different products available in the country.

Viscosupplementation procedure is an effective alternative for patients nonresponsive to other treatment options for osteoarthritis. These products have been clinically proven to be effective in providing long-term relief to OA patients with very few side-effects.

Factors, such as the growing awareness regarding effective non-surgical procedures for the management of OA and global increase in the target population due to the increasing prevalence of obesity and other lifestyle-induced disorders, are expected to propel the market growth during the forecast period.

Further key findings from the study suggest:

    --  Three injections segment dominated the market in 2019 owing to the
        availability of multiple products and significant market presence
    --  Single injection segment is anticipated to witness the fastest growth
        during the forecast period owing to the increase in demand for a shorter
        regimen of procedures and faster recovery time
    --  The utilization of viscosupplementation is maximum in Ambulatory
        Surgical Centers (ASCs), and orthopedic clinics. The higher usage of the
        viscosupplements is observed to be in outpatient settings owing to
        better reimbursement options
    --  General physicians, rheumatologists, and orthopedists are the main
        influencer in the viscosupplementation market. The role of an influencer
        in the procurement of the product in the hospitals and clinics varies
        from region to region
    --  Asia Pacific held the largest market share in 2019 and is expected to
        maintain its position during the forecast period due to the presence of
        key players and high incidence of osteoarthritis in the countries such
        as Japan and China.
    --  Europe is expected to witness a lucrative CAGR in the forthcoming years,
        due to growing awareness about applications of non-surgical techniques
        and increasing disposable income
    --  Key players are investing in improving their product portfolio to
        develop advanced products to maintain their market position. For
        instance, in March 2019, Seikagaku Corporation introduced a new
        intra-articular viscosupplement named HyLink (single injection) in Italy
        for the treatment of knee OA
    --  Companies are also undertaking strategic initiatives, such as marketing
        licensing and distribution partnerships to increase geographic presence
    --  Some key industry contributors are Anika Therapeutics, Inc., Sanofi,
        Ferring B.V., Seikagaku Corporation, Bioventus, Zimmer Holdings Inc, LG
        Life Sciences Ltd, and Lifecore Biomedical, LLC

Key Topics Covered

Chapter 1 Research Objective

Chapter 2 Executive Summary

Chapter 3 Market Variables, Trends & Scope
3.1 Market Lineage Outlook
3.1.1 Parent Market Outlook
3.1.2 Related/Ancillary Market Outlook
3.2 Market Segmentation
3.3 User Perspective Analysis
3.3.1 Consumer Behavior Analysis
3.3.2 Market Influencer Analysis
3.4 Penetration & Growth Prospect Mapping
3.4.1 Analysis
3.5 Market Dynamics
3.5.1 Market Driver Analysis
3.5.1.1 Increasing Prevalence of Osteoarthritis Among Geriatric Population
3.5.1.2 New Product Launch
3.5.2 Market Restraint Analysis
3.5.2.1 High Cost and Side Effects Associated with Hyaluronic Acid Cycles
3.6 Business Environment Analysis Tools
3.6.1 Porter's Five Forces Analysis
3.6.2 Viscosupplementation Market - Pestle Analysis
3.7 Clinical Trials
3.8 Major Deals & Strategic Alliances Analysis
3.8.1 Licensing & Partnerships, Technology Collaborations
3.8.2 Mergers & Acquisitions

Chapter 4 Viscosupplementation Market: Product Analysis
4.1 Viscosupplementation Product Market Share analysis, 2019 & 2027
4.2 Segment Dashboard
4.3 Market Size & Forecasts and Trend Analysis, 2016 to 2027 for the Product
4.3.1 Single Injection
4.3.2 Three Injection
4.3.3 Five Injection
4.3.4 Product Information

Chapter 5 Viscosupplementation Market: End-use Analysis
5.1 Viscosupplementation End-use Market Share analysis, 2019 & 2027
5.2 Segment Dashboard
5.3 Market Size & Forecasts and Trend Analysis, 2016 to 2027 for the End-use
5.3.1 Hospitals
5.3.2 Orthopedic Clinics/Ambulatory Surgery Centers (ASCs)

Chapter 6 Regional Outlook
6.1 Regional Market Share Analysis, 2019 & 2027
6.2 Regional Market Snapshot (Countries)
6.3 SWOT Analysis, by Factor
6.3.1 North America
6.3.2 Europe
6.3.3 Asia-Pacific
6.3.4 Latin America
6.3.5 Middle East & Africa
6.4 Market Size, & Forecasts and Trend Analysis, 2019 to 2027

Chapter 7 Reimbursement Outlook
7.1 Direct Medical Costs of Treatment of Osteoarthritis (Percentage Distribution)
7.2 Cost of Products
7.3 Reimbursement by Product
7.3.1 Gel-One
7.3.2 Euflexxa
7.3.3 Synvisc-One
7.3.4 Supartz
7.3.5 Hyalgan
7.3.6 Monovisc
7.3.7 Orthovisc

Chapter 8 Competitive Analysis
8.1 Strategic Framework/ Competition Categorization (Key Innovators, Market Leaders, Emerging Players)
8.2 Vendor Landscape
8.2.1 Company Market Position Analysis (Market Presence, Geographic Presence, Product Portfolio, Startegic Initiatves)
8.3 Company Profiles
8.3.1 Sanofi
8.3.2 Anika Therapeutics Inc.
8.3.3 Seikagaku Corporation
8.3.4 Zimmer Biomet
8.3.5 Smith & Nephew plc
8.3.6 Ferring B.V.
8.3.7 Lifecore Biomedical, LLC (Landec)
8.3.8 LG Life Sciences Ltd. (LG Chem)
8.3.9 Salix Pharmaceuticals
8.3.10 Fidia Farmaceutic S.p.A
8.3.11 F.Hoffmann-La Roche Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/anqwov

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/viscosupplementation-market-forecast-to-2027-analyzed-by-product-single-three-five-injection-and-end-use-hospitals-orthopedic-clinicsascs-301022348.html

SOURCE Research and Markets